Develops and commercializes pharmaceutical products for rare diseases and conditions, focusing on improving patient access and adherence to treatment.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to advancing and commercializing pharmaceutical products primarily focused on addressing rare diseases. The company's diverse portfolio includes innovative treatments such as Biorphen, a phenylephrine injection used to manage clinically significant hypotension during anesthesia-induced vasodilation. Eton Pharmaceuticals also offers Carglumic Acid, indicated for acute and chronic hyperammonemia resulting from N-acetylglutamate Synthase deficiency, and Rezipres, a ready-to-use formulation targeting anesthesia-related hypotension.
Among its specialized therapies, Eton Pharmaceuticals provides Alkindi Sprinkle, designed as a replacement therapy for adrenocortical insufficiency in children under 17 years old, and EPRONTIA, a liquid formulation of topiramate. Their product line also includes Alaway Preservative Free, an ophthalmic solution tailored for treating allergic conjunctivitis without preservatives. The company is actively developing additional treatments such as Zonisamide Oral Suspension and Lamotrigine Oral Suspension for managing partial onset seizures, as well as innovative formulations like a cysteine injection, dehydrated alcohol injection, and Zeneo hydrocortisone autoinjector.
Founded in 2017 and headquartered in Deer Park, Illinois, Eton Pharmaceuticals continues to expand its footprint in the pharmaceutical industry through strategic development and collaboration efforts. With a commitment to addressing unmet medical needs and enhancing patient care, Eton Pharmaceuticals remains focused on delivering novel therapies that make a meaningful impact in the treatment of rare diseases worldwide.